von Willebrand disease
Conditions
Interventions
Trade Name: Optivate
Product Name: Optivate
Product Code: N/A
Pharmaceutical Form: Powder and solvent for solution for injection
Sponsors
Bio Products Laboratory
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Have given written informed consent.2. Be aged 12 years or older.3. Have VWD of known type.4. Be due to undergo surgery, in which the investigator believes a VWF concentrate will be required.5. Have a known lack of, or poor response to DDAVP, or require a specific type of surgery in which a plasma-derived product is appropriate.6. Have a prothrombin time (PT) of not more than 3 seconds above the upper limit of the reference range. Female patients of child-bearing potential, with the exception of pregnant patients undergoing Caesarean surgery or normal delivery, must have a negative result on a human chorionic gonadotropin-based pregnancy test. If a female patient is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Have a history of inhibitor development to VWF or FVIII or a positive result at screening (positive screen for VWF inhibitor; positive screen and a result of > 0.5 BU for FVIII inhibitor).2. Presence of clinically significant renal disease, liver disease, thrombocytopenia or any other major systemic illnesses which would compromise the outcome of the study in the opinion of the investigator.3. Known or suspected hypersensitivity to investigational medicinal product (IMP) or its excipients.4. Have a recent history of alcohol or drug abuse.5. Administration of a new chemical entity within the 4 months preceding enrolment.6. Participation in any other clinical study in which investigational or marketed drugs were employed in the 30 days preceding enrolment into this study, with the exception of the BPL clinical study Protocol 8VWF01.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the efficacy of OPTIVATE® in preventing excessive blood loss during and after surgery.;Secondary Objective: To assess the safety of OPTIVATE® during and after surgery.;Primary end point(s): The primary end point is excessive blood loss, which will be will be assessed by a subjective assessment by the investigator of Optivate in the control of bleeding due to surgery throughout the whole study. | — |
Countries
Poland, United Kingdom
Outcome results
None listed